WallStreetZenWallStreetZen

NASDAQ: VRNA
Verona Pharma PLC Stock Forecast, Predictions & Price Target

Analyst price target for VRNA

Based on 2 analysts offering 12 month price targets for Verona Pharma PLC.
Min Forecast
$32.00+102.53%
Avg Forecast
$32.50+105.7%
Max Forecast
$33.00+108.86%

Should I buy or sell VRNA stock?

Based on 2 analysts offering ratings for Verona Pharma PLC.
Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their VRNA stock forecasts and price targets.

VRNA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-03-04
lockedlocked$00.00+00.00%2024-03-01

1 of 1

Forecast return on equity

Is VRNA forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
36.1%

Forecast return on assets

Is VRNA forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

VRNA revenue forecast

What is VRNA's revenue in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
$25.6M
Avg 2 year Forecast
$137.3M
Avg 3 year Forecast
$276.9M

VRNA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
VRNA$15.80$32.50+105.70%Buy
AUTL$4.90$9.50+93.88%Strong Buy
SLNO$38.52$60.75+57.71%Strong Buy
FDMT$26.25$50.71+93.20%Strong Buy
KNSA$17.44$25.00+43.35%Buy

Verona Pharma Stock Forecast FAQ

Is Verona Pharma Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: VRNA) stock is to Buy VRNA stock.

Out of 2 analysts, 0 (0%) are recommending VRNA as a Strong Buy, 2 (100%) are recommending VRNA as a Buy, 0 (0%) are recommending VRNA as a Hold, 0 (0%) are recommending VRNA as a Sell, and 0 (0%) are recommending VRNA as a Strong Sell.

If you're new to stock investing, here's how to buy Verona Pharma stock.

What is VRNA's revenue growth forecast for 2024-2026?

(NASDAQ: VRNA) Verona Pharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.51%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.3%.

Verona Pharma's revenue in 2024 is $0.On average, 5 Wall Street analysts forecast VRNA's revenue for 2024 to be $16,563,969,424, with the lowest VRNA revenue forecast at $5,172,199,664, and the highest VRNA revenue forecast at $29,630,238,825. On average, 5 Wall Street analysts forecast VRNA's revenue for 2025 to be $88,743,308,785, with the lowest VRNA revenue forecast at $64,652,495,800, and the highest VRNA revenue forecast at $107,517,100,515.

In 2026, VRNA is forecast to generate $179,018,235,195 in revenue, with the lowest revenue forecast at $150,439,892,477 and the highest revenue forecast at $218,518,970,554.

What is VRNA's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: VRNA) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is VRNA's Price Target?

According to 2 Wall Street analysts that have issued a 1 year VRNA price target, the average VRNA price target is $32.50, with the highest VRNA stock price forecast at $33.00 and the lowest VRNA stock price forecast at $32.00.

On average, Wall Street analysts predict that Verona Pharma's share price could reach $32.50 by Mar 4, 2025. The average Verona Pharma stock price prediction forecasts a potential upside of 105.7% from the current VRNA share price of $15.80.

What is VRNA's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: VRNA) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.